Clinical impact of ki-67 labeling index in non-small cell lung cancer
- 31 January 2013
- journal article
- review article
- Published by Elsevier BV in Lung Cancer
- Vol. 79 (1), 1-7
- https://doi.org/10.1016/j.lungcan.2012.10.008
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issuesLung Cancer, 2011
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of TherapyJournal of Thoracic Oncology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung CancerJournal of Thoracic Oncology, 2007
- Chromophore‐assisted light inactivation of pKi‐67 leads to inhibition of ribosomal RNA synthesisCell Proliferation, 2007
- Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cellsJournal of Cellular Physiology, 2005
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983